InVivo Therapeutics Holdings Corp. (NVIV) announced today that Tom Ulich, MD, InVivo’s Chief Scientific Officer, will present at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.

Dr. Ulich's presentation will take place at 3:00PM PDT on Tuesday, October 7th at the Estancia La Jolla Hotel. A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on the Alliance for Regerative Medicine’s website shortly after the event.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2014 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior executives and top decision makers in the regenerative medicine industry with the scientific community to advance cutting-edge research into cures. The Partnering Forum is the first and only partnering meeting of its kind dedicated solely to facilitating connections for the regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract nearly 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field. For more information, please visit: http://stemcellmeetingonthemesa.com/

Dr. Ulich said, “As we advance towards the clinic with our human neural stem cell-coated Neural Spinal Scaffold, we look forward to illustrating the benefits of our approach to the reconstitution of neural connectivity in the spinal cord of patients with chronic motor and sensory impairment.”

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.